174 related articles for article (PubMed ID: 9207379)
1. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
Merrill DP; Manion DJ; Chou TC; Hirsch MS
J Infect Dis; 1997 Jul; 176(1):265-8. PubMed ID: 9207379
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
3. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
Korting HC; Schaller M; Eder G; Hamm G; Böhmer U; Hube B
Antimicrob Agents Chemother; 1999 Aug; 43(8):2038-42. PubMed ID: 10428932
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of indinavir and saquinavir confirmed.
Bartnof HS
BETA; 1997 Sep; ():45. PubMed ID: 11364702
[TBL] [Abstract][Full Text] [Related]
7. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.
Tremblay C; Merrill DP; Chou TC; Hirsch MS
J Acquir Immune Defic Syndr; 1999 Dec; 22(5):430-6. PubMed ID: 10961603
[TBL] [Abstract][Full Text] [Related]
8. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
Descamps D; Apetrei C; Collin G; Damond F; Simon F; Brun-Vézinet F
AIDS; 1998 Jun; 12(9):1109-11. PubMed ID: 9662212
[No Abstract] [Full Text] [Related]
10. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
[TBL] [Abstract][Full Text] [Related]
11. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.
Armbruster C; Vorbach H; Steindl F; El Menyawi I
J Antimicrob Chemother; 2001 Apr; 47(4):487-90. PubMed ID: 11266428
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
[TBL] [Abstract][Full Text] [Related]
13. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 protease inhibitors.
McDonald CK; Kuritzkes DR
Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
16. Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
Rodés B; Poveda E; Soriano V
J Clin Microbiol; 2002 Nov; 40(11):4313-6. PubMed ID: 12409418
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
18. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of simian immunodeficiency virus to protease inhibitors.
Giuffre AC; Higgins J; Buckheit RW; North TW
Antimicrob Agents Chemother; 2003 May; 47(5):1756-9. PubMed ID: 12709355
[TBL] [Abstract][Full Text] [Related]
20. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
